Traders Purchase High Volume of Teva Pharmaceutical Industries Call Options (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVAGet Rating) was the recipient of some unusual options trading on Tuesday. Stock traders acquired 84,484 call options on the stock. This is an increase of approximately 254% compared to the typical daily volume of 23,889 call options.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Institutional investors and hedge funds have recently bought and sold shares of the stock. Private Trust Co. NA bought a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter worth approximately $32,000. Credit Agricole S A bought a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter worth approximately $34,000. Aaron Wealth Advisors LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter worth approximately $603,000. Newbridge Financial Services Group Inc. grew its position in shares of Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. Newbridge Financial Services Group Inc. now owns 5,900 shares of the company’s stock worth $48,000 after buying an additional 5,000 shares during the last quarter. Finally, Edmond DE Rothschild Holding S.A. grew its position in shares of Teva Pharmaceutical Industries by 213.8% in the 3rd quarter. Edmond DE Rothschild Holding S.A. now owns 6,678 shares of the company’s stock worth $54,000 after buying an additional 4,550 shares during the last quarter. 46.22% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on TEVA. StockNews.com began coverage on Teva Pharmaceutical Industries in a report on Wednesday, October 12th. They issued a “buy” rating on the stock. Jefferies Financial Group reaffirmed a “buy” rating and issued a $10.00 price target on shares of Teva Pharmaceutical Industries in a report on Friday, October 21st. BMO Capital Markets lowered their price target on Teva Pharmaceutical Industries from $11.00 to $10.00 and set a “market perform” rating on the stock in a report on Monday, November 7th. UBS Group cut Teva Pharmaceutical Industries from a “neutral” rating to a “sell” rating in a report on Friday, November 4th. Finally, Bank of America raised Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and raised their price objective for the company from $10.00 to $13.00 in a report on Friday, August 5th. Three analysts have rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Hold” and a consensus target price of $10.44.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA opened at $8.80 on Thursday. The stock’s 50-day moving average is $8.54 and its 200 day moving average is $8.63. The company has a current ratio of 0.99, a quick ratio of 0.66 and a debt-to-equity ratio of 1.94. Teva Pharmaceutical Industries has a 1-year low of $6.78 and a 1-year high of $11.34. The stock has a market cap of $9.77 billion, a price-to-earnings ratio of -7.59 and a beta of 1.27.

Teva Pharmaceutical Industries (NYSE:TEVAGet Rating) last posted its quarterly earnings results on Thursday, November 3rd. The company reported $0.56 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.58 by ($0.02). Teva Pharmaceutical Industries had a positive return on equity of 26.97% and a negative net margin of 8.52%. The company had revenue of $3.60 billion for the quarter, compared to the consensus estimate of $3.86 billion. On average, sell-side analysts anticipate that Teva Pharmaceutical Industries will post 2.42 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

(Get Rating)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.

Further Reading

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.